ZD 1839 (IRESSA™): Preclinical studies and pharmacology

Tumori

Volumn 88, Issue SUPPL. 1, 2002, Pages

  Ciardiello, Fortunato ^a   Tortora, Giampaolo ^a   De Placido, Sabino ^a   Bianco, A Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; RASH; AGE; AGED; ARTICLE; DRUG ANTAGONISM; METABOLISM; NEOPLASM;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036198508     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800145     Document Type: Conference Paper

References (11)

1. The epidermal growth factor receptor and its inhibition in cancer therapy
2. Epidermal growth factor-related peptides and their receptors in human malignancies
3. Blockade of receptors for growth factors: An anticancer therapy
4. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
5. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor
6. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
7. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
8. Continuous administration of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
9. Final results of the dose-escalation phase of a phase I 1, dose-escalation, pharmacokinetics (PK) and pharmacodynamic study of ZD1839: NCIC CTG IND.122
10. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSLC)
11. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular conbsequences of receptor inhibition